Mimetogen Pharmaceuticals USA, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.mimetogen.com
Clinical Trials
6
Active:0
Completed:6
Trial Phases
2 Phases
Phase 2:1
Phase 3:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 3
5 (83.3%)Phase 2
1 (16.7%)Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Phase 3
Completed
- Conditions
- Dry Eye SyndromesDry Eye DiseaseKerato Conjunctivitis Sicca
- Interventions
- Drug: 5% Tavilermide ophthalmic solutionOther: Vehicle ophthalmic solution
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 642
- Registration Number
- NCT05848128
- Locations
- 🇺🇸
Eye Doctors of Arizona, Phoenix, Arizona, United States
🇺🇸Global Research Management, Glendale, California, United States
🇺🇸LoBue Laser and Eye Medical Center, Murrieta, California, United States
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Phase 3
Completed
- Conditions
- Dry EyeKeratoconjunctivitis Sicca
- Interventions
- Other: Placebo
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 623
- Registration Number
- NCT03925727
- Locations
- 🇺🇸
Tavilermide Investigational Site, Kenosha, Wisconsin, United States
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
Phase 3
Completed
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Drug: Placebo Ophthalmic Solution
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT02665234
- Locations
- 🇺🇸
MIM-726 Investigational Site, Torrance, California, United States
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye
Phase 3
Completed
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Drug: Placebo Ophthalmic Solution
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 429
- Registration Number
- NCT02634853
- Locations
- 🇺🇸
MIM-727 Investigational Site, Nashville, Tennessee, United States
A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
Phase 3
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: MIM-D3 Ophthalmic SolutionDrug: Vehicle
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT01960010
- Locations
- 🇺🇸
MIM-725 Investigational Site, Memphis, Tennessee, United States
- Prev
- 1
- 2
- Next
News
No news found